New drug may free hypoparathyroidism patients from daily calcium pills
NCT ID NCT07299838
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug, palopegteriparatide, in 90 adults with chronic hypoparathyroidism. The goal was to see if the drug could help patients stop taking activated vitamin D and calcium supplements for at least four weeks. Researchers tracked how long it took to become supplement-free and monitored safety. The study was completed in Greece and provides real-world evidence on this treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Laiko General Hospital
Athens, Attica, 11527, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a daily shot free teens from calcium pills?
- Weekly shot could free hypoparathyroidism patients from daily pills
- New daily shot could ease rare hormone disorder
- Glowing goggles could prevent calcium crash after thyroid surgery
- MRNA therapy offers hope for rare hormone disorder
- MRNA therapy takes on rare hormone disorder